van Oosten BW - Search Results

1

Natalizumab drug holiday in multiple sclerosis: poorly tolerated.

Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH. Killestein J, et al. Among authors: van oosten bw. Ann Neurol. 2010 Sep;68(3):392-5. doi: 10.1002/ana.22074. Ann Neurol. 2010. PMID: 20661928

2

Interleukin-1 receptor antagonist gene polymorphism and multiple sclerosis.

Crusius JB, Peña AS, Van Oosten BW, Bioque G, Garcia A, Dijkstra CD, Polman CH. Crusius JB, et al. Among authors: van oosten bw. Lancet. 1995 Oct 7;346(8980):979. Lancet. 1995. PMID: 7564774 No abstract available.

3

Multiple sclerosis therapy. A practical guide.

van Oosten BW, Truyen L, Barkhof F, Polman CH. van Oosten BW, et al. Drugs. 1995 Feb;49(2):200-12. doi: 10.2165/00003495-199549020-00005. Drugs. 1995. PMID: 7729328 Review.

4

Accumulation of hypointense lesions ("black holes") on T1 spin-echo MRI correlates with disease progression in multiple sclerosis.

Truyen L, van Waesberghe JH, van Walderveen MA, van Oosten BW, Polman CH, Hommes OR, Adèr HJ, Barkhof F. Truyen L, et al. Among authors: van walderveen ma, van oosten bw, van waesberghe jh. Neurology. 1996 Dec;47(6):1469-76. doi: 10.1212/wnl.47.6.1469. Neurology. 1996. PMID: 8960729

5

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, Woody JN, Hartung HP, Polman CH. van Oosten BW, et al. Neurology. 1996 Dec;47(6):1531-4. doi: 10.1212/wnl.47.6.1531. Neurology. 1996. PMID: 8960740

6

A pilot study investigating the effects of orally administered pentoxifylline on selected immune variables in patients with multiple sclerosis.

van Oosten BW, Rep MH, van Lier RA, Scholten PE, von Blomberg BM, Pflughaupt KW, Hartung HP, Adèr HJ, Polman CH. van Oosten BW, et al. Among authors: van lier ra. J Neuroimmunol. 1996 May;66(1-2):49-55. doi: 10.1016/0165-5728(96)00019-7. J Neuroimmunol. 1996. PMID: 8964913 Clinical Trial.

7

TNF-alpha promoter polymorphisms, production and susceptibility to multiple sclerosis in different groups of patients.

Huizinga TW, Westendorp RG, Bollen EL, Keijsers V, Brinkman BM, Langermans JA, Breedveld FC, Verweij CL, van de Gaer L, Dams L, Crusius JB, García-Gonzalez A, van Oosten BW, Polman CH, Peña AS. Huizinga TW, et al. Among authors: van oosten bw, van de gaer l. J Neuroimmunol. 1997 Feb;72(2):149-53. doi: 10.1016/s0165-5728(96)00182-8. J Neuroimmunol. 1997. PMID: 9042107

8

Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans.

Rep MH, van Oosten BW, Roos MT, Adèr HJ, Polman CH, van Lier RA. Rep MH, et al. Among authors: van lier ra, van oosten bw. J Clin Invest. 1997 May 1;99(9):2225-31. doi: 10.1172/JCI119396. J Clin Invest. 1997. PMID: 9151795 Free PMC article. Clinical Trial.

9

Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial.

van Oosten BW, Lai M, Hodgkinson S, Barkhof F, Miller DH, Moseley IF, Thompson AJ, Rudge P, McDougall A, McLeod JG, Adèr HJ, Polman CH. van Oosten BW, et al. Neurology. 1997 Aug;49(2):351-7. doi: 10.1212/wnl.49.2.351. Neurology. 1997. PMID: 9270561 Clinical Trial.

10

Interleukin-2 therapy does not exacerbate multiple sclerosis.

van Oosten BW, Uitdehaag BM, Barkhof F, Hartung HP, Wagstaff J, Polman CH. van Oosten BW, et al. Neurology. 1997 Aug;49(2):633-4. doi: 10.1212/wnl.49.2.633. Neurology. 1997. PMID: 9270618 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

77 results

Search Page